Drugs / Luveltamab tazevibulin
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05200364 | Mar 2022 → Jun 2025 | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Sutro Biopharma, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03748186 | Feb 2019 → Jun 2024 | endometrial cancer, endometrioid adenocarcinoma, fallopian tube cancer, ovarian carcinoma +1 | Sutro Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06679582 | Dec 2024 → Jun 2025 | acute myeloid leukemia | Sutro Biopharma, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT06238687 | Nov 2023 → Jun 2025 | cancer | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06555263 | Aug 2024 → May 2025 | non-small cell lung carcinoma | Sutro Biopharma, Inc. | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05870748 | Jul 2023 → Aug 2025 | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sutro Biopharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Luveltamab tazevibulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05870748 ↗ |
| Known as | Luveltamab tazevibulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095133 ↗ |
| Known as | Luveltamab tazevibuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095133 ↗ |
| Known as | SP-8193 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095133 ↗ |
| Known as | STRO-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03748186 ↗ |
| Action | Inhibit | “The active warhead (SC209) inhibits tubulin polymerization” NCT06679582 ↗ |
| Modality | Monoclonal antibody | “It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload” NCT06679582 ↗ |
| Route | Intravenous | “Study drug, STRO-002, is administered by intravenous (IV) infusion on day 1 of 21-day cycles.” NCT03748186 ↗ |
| Target | FOLR1 | “Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1.” NCT05870748 ↗ |